Phosphoglycerate kinase is a central leverage point in Parkinson’s disease–driven neuronal metabolic deficits
Published August 21, 2024
Output Details
Preprint October 16, 2023
Published August 21, 2024
Description
PAlthough certain drivers of familial Parkinson’s disease (PD) compromise mitochondrial integrity, whether metabolic deficits underly other idiopathic or genetic origins of PD is unclear. Here, we demonstrate that phosphoglycerate kinase 1 (PGK1), a gene in the PARK12 susceptibility locus, is rate limiting in neuronal glycolysis and that modestly increasing PGK1 expression boosts neuronal adenosine 5′-triphosphate production kinetics that is sufficient to suppress PARK20-driven synaptic dysfunction. We found that this activity enhancement depends on the molecular chaperone PARK7/DJ-1, whose loss of function significantly disrupts axonal bioenergetics. In vivo, viral expression of PGK1 confers protection of striatal dopamine axons against metabolic lesions. These data support the notion that bioenergetic deficits may underpin PD-associated pathologies and point to improving neuronal adenosine 5′-triphosphate production kinetics as a promising path forward in PD therapeutics.
Identifier (DOI)
10.1126/sciadv.adn6016
